Lower Urinary Tract Symptoms Clinical Trial
Official title:
Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms: a Phase I-II Study
Baobab oil is often used in traditional medicine as antipyretic, antioxidant, anti-inflammatory, analgesic and antimicrobial. It also regenerates the epithelial tissue in a short time improving tone and elasticity. We want to evaluate the effects of intravesical Baobab oil in patients with BCG-induced lower urinary tract symptoms.
After complete transurethral resection of primary high risk non-muscle invasive bladder
tumors (stage pTa, pT1, carcinoma in situ and high grade urothelial carcinoma), patients on
induction course of intravesical BCG with lower urinary tract symptoms unresponsive to
standard therapies are enrolled. The patients supply written informed consent to a document
describing the investigational nature of the protocol.
Induction treatment consists of an initial 6 intravesical BCG treatments at weekly interval
commencing approximately 3 weeks after transurethral resection procedures. The BCG
instillation consisted of 81 mg wet weight (10•2±9•0 x 108 colony-forming units) BCG
Connaught substrain. Lyophilised (ie, freeze-dried) BCG is suspended in 50 mL
bacteriostatic-free solution of 0•9% sodium chloride. After draining of the bladder, the
suspension is infused intravesically through a Foley catheter. The solution is retained in
the bladder for 120 min, followed by emptying of the bladder and removal of the catheter.
During BCG treatment patients with persistent lower urinary tract symptoms unresponsive to
standard therapies (anticholinergics, alpha-blockers, antibiotics, analgesics and
anti-inflammatory drugs) are treated with an intravesical instillation of 50 ml sterile
Baobab natural oil (Baotrophic, Physion Srl, Mirandola, Italy). After draining of the
bladder, the suspension is infused intravesically through a Foley catheter. The solution is
retained in the bladder for 60 min, followed by emptying of the bladder and removal of the
catheter.
Lower urinary tract symptoms are self-recorded by the patients before and after each baobab
oil instillation and classified by the investigator according to a classification grid
considering account duration and intensity. The classification of symptoms is class 0= none,
class I = mild, class II = moderate, and class III = severe, according to severity. Local
adverse events are cystitis, nocturia, pollakiuria, micturition urgency, micturition
burning, stress urinary incontinence, dysuria, hematuria, pelvic pain, and perineal pain.
The outcome measures are analyzed before and every day for one week after treatment. All
patients are assessed for safety.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04856748 -
Nomogram to Diagnose Prostatic Inflammation (PIN) in Men With Lower Urinary Tract Symptoms
|
||
Completed |
NCT03623880 -
Enhancing Behavioral Treatment for Women With Pelvic Floor Disorders
|
N/A | |
Enrolling by invitation |
NCT06317116 -
Examining the Relationship Between Core Muscles and Bladder Issues in Children
|
||
Completed |
NCT03625843 -
Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing
|
N/A | |
Recruiting |
NCT05814614 -
Bladder Complaints in Parkinson's Disease Effectiveness of Pelvic Floor Muscle Exercises and Electrical Stimulation
|
N/A | |
Recruiting |
NCT04288427 -
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
|
N/A | |
Not yet recruiting |
NCT06452927 -
EEP in Patients With Urodynamically Proven DU/DA
|
N/A | |
Completed |
NCT02330107 -
Auriculotherapy on Lower Urinary Tract Symptoms in Elderly Men
|
N/A | |
Completed |
NCT03339609 -
Uroflow Measurement With Electromyography (EMG) to Identify Lower Urinary Tract Symptoms (LUTS): Conducted on Healthy Children
|
N/A | |
Terminated |
NCT02003742 -
Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH
|
Phase 3 | |
Terminated |
NCT01003249 -
Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
|
Phase 4 | |
Completed |
NCT01078545 -
Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)
|
N/A | |
Completed |
NCT02074644 -
Clinical Trial of Prostatic Arterial Embolization Versus a Sham Procedure to Treat Benign Prostatic Hyperplasia
|
N/A | |
Recruiting |
NCT03802851 -
HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT05415748 -
Deprescribing Tamsulosin in Older Men
|
Phase 4 | |
Recruiting |
NCT05702294 -
Electronic Urinary Flowmeter to Improve Accuracy of Bladder Diaries .
|
N/A | |
Enrolling by invitation |
NCT05537272 -
The Efficacy of Tamsulosin and Tadalafil Compared to Placebo in the Treatment and Prevention of Urinary Disorders After Transperineal Prostate Biopsy
|
Phase 4 | |
Recruiting |
NCT05826691 -
Benign Prostate Surgery and QOL and Sexual Function
|
||
Completed |
NCT04104100 -
Prevalence and Risk Factor of NP in Women With LUTS
|
||
Completed |
NCT04190641 -
Single-use Cystoscope System for Direct Visualization of the Urethra and Bladder
|
N/A |